Eli Lilly Stock Falls After Release of New Alzheimer's Drug Data (NYSE: LLY)

The Eli Lilly stock price fell as much as 4.8% this morning (Wednesday) after the company released new trial results on its Alzheimer's drug solanezumab. Eli Lilly and Co. (NYSE: LLY) officials released data from a follow-up study on two of the drug's earlier trials. The Alzheimer's drug fell short of its goals in the first two trials, but the new data showed encouraging signs. Here's everything investors need to know now... Tags: Eli Lilly Alzheimer's , Eli Lilly stock , Eli Lilly stock price , Eli Lilly stock price today , LLY stock , LLY stock price , NYSE: LLY To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Eli Lilly Stock Falls After Release of New Alzheimer's Drug Data (NYSE: LLY) appeared first on Money Morning - We Make Investing Profitable .